About: Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 23 August 2010

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в жовтні 2010 (uk) artículu científicu espublizáu n'agostu de 2010 (ast) scientific article published on 23 August 2010 (en) article scientifique publié en août 2010 (fr) im August 2010 veröffentlicher wissenschaftlicher Artikel (de)
publication date	wds:Q60203634-E45A3631-DAF3-4BF0-802C-D5F75A685DAE
publication date	2010-08-23 00:00:00Z (xsd:dateTime)
cites work	wds:Q60203634-100D46D2-824C-4286-B3D0-DC6E041B67CD wds:Q60203634-10522CB8-B64E-4CAF-B4C2-077F9C4F7B27 wds:Q60203634-300B9EC2-6AC9-4A99-A77F-BDF3211E01A2 wds:Q60203634-38B72818-7DAA-4850-A964-8B7498318D35 wds:Q60203634-39FB9E22-F12A-4091-8BEF-70A4B41BDF2E wds:Q60203634-53100612-2E9C-4D5D-8053-7E3C6FF5E0C1 wds:Q60203634-5626F142-12A4-44E9-B51F-297BEF2AE72C wds:Q60203634-5E02D0D9-B247-4FF6-9E7F-269854352ACC wds:Q60203634-64DE399F-EAA6-430C-B3BC-3F5BDA510902 wds:Q60203634-6CFF2CDE-1FE6-480E-A94E-1306B2A84488 wds:Q60203634-8941B230-7630-4018-83C3-4FACBBC0081B wds:Q60203634-92199BFF-0203-4A24-A548-6B237E86AB1D wds:Q60203634-925F8910-6333-4226-B7B4-920BDDD58F15 wds:Q60203634-A4E3D49A-DD58-43C9-B22D-EBA4BA66D71C wds:Q60203634-B67885F4-A8A2-40C8-92C2-53BF1D4AA47F wds:Q60203634-C107BFCD-7B80-436E-A19E-251528D99783 wds:Q60203634-CB21ACDF-5819-4E32-B9C5-66AE795AC5FE wds:Q60203634-CB259FCD-FD26-4AC4-812B-B98E1988FEE3 wds:Q60203634-D5551300-E1DE-4138-84C6-8C4A7DDB6A16 wds:Q60203634-D8159DD9-E8FA-4675-ADD8-930493CE1D37 wds:Q60203634-E97A894F-EB85-4562-B453-C38C2756D894 wds:Q60203634-EC262AA0-D29F-48AD-972D-BD525CF8801B
cites work	Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation Hazard Rate Models with Covariates Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone Cox regression methods for two-stage randomization designs. Two-stage randomization designs in drug development
author name string	wds:Q60203634-199AF495-8D2E-4C08-B272-B5736356096B wds:Q60203634-2A0CC20D-EF9C-40CB-BCE1-AE28220AE848 wds:Q60203634-5E8F611C-7ECC-4C31-ACB4-8FAFEF56B6EE wds:Q60203634-8B1B0580-6AFA-4CFD-8735-63AFBC7A5F20 wds:Q60203634-CDCA1BB8-7B99-406E-8284-E401D4E365F9 wds:Q60203634-EB360E0D-13DD-48DF-9263-36F12D8237BD
author name string	Yolanda González Raquel de Paz Luis Palomera Alejandro Martín Francisco-Javier Peñalver Jose-Mariano Hernández
rdfs:label	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m (en) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m (nl)
skos:prefLabel	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m (en) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m (nl)
name	Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m (en) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple m (nl)
author	wds:Q60203634-00660CBD-A436-44EC-808B-A4480F304D69 wds:Q60203634-05D574E8-0242-4A5F-A26A-3471C4C93429 wds:Q60203634-32A03570-B947-4D4C-A19B-2562A525AB93 wds:Q60203634-396CB309-9213-49E0-8BCC-7F53D2645959 wds:Q60203634-39E74A2C-0463-4285-8DAD-2AD2CAEF6205 wds:Q60203634-3B654FF3-87E7-44B9-A7EB-D2A066B63858 wds:Q60203634-44CF6216-A413-4DF7-AA6F-01F3C0E20BB0 wds:Q60203634-4BFE1A17-819E-4FB8-A762-7A242A53D366 wds:Q60203634-4F45DC06-EF9B-4CA3-BE4A-A2E20CC521C7 wds:Q60203634-503E864D-717E-45E5-9010-FB4B651C2ACB wds:Q60203634-508ECC2E-4977-4725-83A0-3B1DA5359592 wds:Q60203634-6254D45A-53DC-4F83-893C-ACE1FB8C6338 wds:Q60203634-69BD027F-87E6-48FE-B04C-650CD0C2CE22 wds:Q60203634-78BC9B15-65C4-4A13-A15B-CC8F3470720A wds:Q60203634-78FF5C7E-6072-4A28-B548-5FFFE5B5D8CA wds:Q60203634-79884E02-957B-4CC0-B778-3B5774A8B955 wds:Q60203634-95C1720B-9DC4-4C9A-BB62-49812C04F4B3 wds:Q60203634-A4DC3A71-EBF7-4268-9680-C6F25A29A83D wds:Q60203634-AE7E6E3D-6D06-4658-8DD4-035E49F6087A wds:Q60203634-D6783A13-1211-4B08-A4FD-5255881AED2C wds:Q60203634-E06504C0-E459-4C89-A50D-762B5B218D33 wds:Q60203634-FA95819A-6135-44FD-9AE3-C09B6354BD89 wds:Q60203634-FF7E0C4E-2209-4B34-844B-DD663486CC70
author	Norma C. Gutiérrez Joaquin Martinez-Lopez Maria Teresa Cibeira Joan Bladé Jesús San Miguel Albert Oriol

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software